Look for Drugs and Conditions

Representative image

Sun Pharma acquires 3 proteolytic enzyme-based drugs to bolster its anti-inflammatory basket

Indian pharmaceutical major Sun Pharmaceuticals announced on January 30, 2023, that it has acquired three proteolytic enzyme-based drug formulations from Mumbai-based research-driven healthcare entity Aksigen Hospital Care, to further strengthen its anti-inflammatory portfolio.

In a statement, the company informed that it has acquired Trypsin Bromelain and Rutoside Trihydrate and combination drugs marketed as Disperzyme, Disperzyme-CD and Phlogam, approved by the Drugs Controller General of India (“DCGI”) for inflammation in patients undergoing minor surgery and dental procedures.

While Trypsin, a proteolytic enzyme, is primarily related to enhancing fibrinolysis or breaking down of blood clotting by making more plasmin available for action, Bromelain, another proteolytic enzyme, has broad-ranging effects of limiting vascular permeability, thereby can help to counter oedema, inhibiting platelet aggregation to counter thrombosis and limiting inflammatory cell infiltration.

On the other hand, Rutoside, a bioflavonoid, has far-reaching effects in controlling oxidative stress and vascular permeability and countering the activation of and further release of inflammatory cytokines and chemokines.

Announcing the acquisition, Kirti Ganorkar, CEO-India business at Sun Pharma, said, “The addition of Disperzyme and Phlogam further strengthens our anti-inflammatory portfolio.”

“This systemic enzyme therapy combination is being used to control oedema, and it speeds up the healing process,” he added.

“In a comparative clinical trial in India, the brands provided significantly better control and resolution of postoperative pain and inflammation,” he further added.

Data from IQVIA data (MAT Nov 2022) estimate that the overall market of proteolytic enzymes for healing, pain and oedema in India is around Rs.500 crores.

Be first to post your comments

Post your comment

Related Articles

Ad 5